ESMO Symposium on Signalling Pathways in Cancer 2016

Oncology Meeting Resources

04 Mar - 05 Mar, Sitges, Spain

Signalling Pathways in Cancer 2016

The objective of the ESMO Symposium on Signalling Pathways in Cancer was to bring together academics, clinical researchers and industry researchers who are actively working in specific tumour settings in order to facilitate knowledge sharing through a series of interactive sessions and workshops.

Presentations and webcasts from the ESMO Symposium on Signalling Pathways in Cancer 2016 are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links

Presenter Presentation title Session title
Nancy Hynes The principles of signal transduction The basis of targeted therapy
Nicola Aceto Circulating biomarkers – CTCs Dissecting the tumour / cancer phenotype
Richard Marais Lessons learned from melanoma resistance Mechanisms of resistance to HER targeting drugs
Livio Trusolino Colorectal cancer Mechanisms of resistance to HER targeting drugs
Fortunato Ciardiello Lung cancer Mechanisms of resistance to HER targeting drugs
Fabrice André Breast cancer Mechanisms of resistance to HER targeting drugs
Andrés Cervantes ESMO Guidelines: How is personalised medicine addressed? Guidelines
Rodrigo Dienstmann Colon cancer Molecular characterisation and subtyping of common tumours
Solange Peters Lung cancer Molecular characterisation and subtyping of common tumours
Patrick Tan Gastric cancer Molecular characterisation and subtyping of common tumours
Salvatore Siena Current status of the treatment of mCRC with EGFR inhibitors Targeting the EGFR/HER family in CRC
Alberto Bardelli Unravelling signal escape: Vertical inhibition Targeting the EGFR/HER family in CRC
Clara Montagut Dynamics of EGFR inhibition: Implications for treatment Targeting the EGFR/HER family in CRC
Benjamin Besse Unravelling signal escape through maintained receptor activation: New treatment options Targeting the EGFR/HER family in NSCLC
Chiara Ambrogio KRAS: From function and genomics to clinical inhibition Targeting the EGFR/HER family in NSCLC